Skip to content

Released Jun 10, 2021, before the open

10-Q filed Jun 10, 2021, 71 days after period end · 0001785530-21-000026

Q1 2021 · 10-Q
Revenue—
Net Income-$7.44MN/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$83.36N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$7,452,000N/M
Operating Cash Flow-$7,326,000N/M
Free Cash Flowderived-$7,339,000N/M

What the release said

The release

Same quarter

MetricQ1 2021Q1 2020
Net Income-$7.44M-$3.83M
EPS Diluted-$83.36-$4.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR